PLx Pharma Inc (PLXP) Receives Average Rating of “Hold” from Brokerages

Shares of PLx Pharma Inc (NASDAQ:PLXP) have earned a consensus rating of “Hold” from the five analysts that are currently covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a sell rating and three have issued a buy rating on the company. The average 12 month target price among brokers that have covered the stock in the last year is $13.00.

A number of brokerages have recently commented on PLXP. ValuEngine raised shares of PLx Pharma from a “strong sell” rating to a “sell” rating in a research report on Monday, December 4th. Zacks Investment Research lowered shares of PLx Pharma from a “hold” rating to a “sell” rating in a research report on Thursday, November 16th. Finally, Janney Montgomery Scott began coverage on shares of PLx Pharma in a research report on Friday, January 19th. They issued a “buy” rating and a $14.00 price objective on the stock.

PLx Pharma (NASDAQ PLXP) opened at $6.25 on Tuesday. The company has a quick ratio of 8.88, a current ratio of 8.99 and a debt-to-equity ratio of 0.56. PLx Pharma has a one year low of $5.60 and a one year high of $12.80.

An institutional investor recently bought a new position in PLx Pharma stock. Brown Advisory Inc. acquired a new position in PLx Pharma Inc (NASDAQ:PLXP) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 110,000 shares of the biotechnology company’s stock, valued at approximately $759,000. Brown Advisory Inc. owned approximately 1.26% of PLx Pharma as of its most recent SEC filing. Institutional investors and hedge funds own 25.54% of the company’s stock.

TRADEMARK VIOLATION WARNING: “PLx Pharma Inc (PLXP) Receives Average Rating of “Hold” from Brokerages” was originally reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright law. The correct version of this piece can be viewed at

PLx Pharma Company Profile

PLx Pharma Inc, formerly Dipexium Pharmaceuticals, Inc, is a biopharmaceutical company. The Company is a late stage specialty pharmaceutical company focusing on commercializing its lead products: Aspertec 325 mg and Aspertec 81 mg (Aspertec). The Company’s products and technology includes PLxGuard delivery system, Aspertec 325 mg, PL1100/PL1200 Ibuprofen.

Receive News & Ratings for PLx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PLx Pharma and related companies with's FREE daily email newsletter.

Leave a Reply